27035-07-0

Upstream product

• 616-02-4 citraconic acid anhydride 
• 626-43-7 3,5-Dichloroaniline 

Downstream Products

• 144835-49-4 (3aR,6aS)-5-(3,5-Dichloro-phenyl)-6a-methyl-3-phenyl-3a,6a-dihydro-pyrrolo[3,4-d]isoxazole-4,6-dione 
• 144835-52-9 (3aR,6aS)-5-(3,5-Dichloro-phenyl)-6a-methyl-3-(3-nitro-phenyl)-3a,6a-dihydro-pyrrolo[3,4-d]isoxazole-4,6-dione 
• 144835-55-2 (3aR,6aS)-3-(2-Chloro-phenyl)-5-(3,5-dichloro-phenyl)-6a-methyl-3a,6a-dihydro-pyrrolo[3,4-d]isoxazole-4,6-dione 
• 144835-57-4 (3aR,6aS)-3-(2,4-Dichloro-phenyl)-5-(3,5-dichloro-phenyl)-6a-methyl-3a,6a-dihydro-pyrrolo[3,4-d]isoxazole-4,6-dione 
• 144835-51-8 (3aR,6aS)-5-(3,5-Dichloro-phenyl)-6a-methyl-3-(2-nitro-phenyl)-3a,6a-dihydro-pyrrolo[3,4-d]isoxazole-4,6-dione 
• 144835-54-1 (3aR,6aS)-5-(3,5-Dichloro-phenyl)-3-(2-fluoro-phenyl)-6a-methyl-3a,6a-dihydro-pyrrolo[3,4-d]isoxazole-4,6-dione 
• 144835-59-6 (3aR,6aS)-3-(2-Bromo-phenyl)-5-(3,5-dichloro-phenyl)-6a-methyl-3a,6a-dihydro-pyrrolo[3,4-d]isoxazole-4,6-dione 
• 144835-60-9 (3aR,6aS)-5-(3,5-Dichloro-phenyl)-6a-methyl-3-(2-trifluoromethyl-phenyl)-3a,6a-dihydro-pyrrolo[3,4-d]isoxazole-4,6-dione 
• 144835-56-3 (3aR,6aS)-3-(4-Chloro-phenyl)-5-(3,5-dichloro-phenyl)-6a-methyl-3a,6a-dihydro-pyrrolo[3,4-d]isoxazole-4,6-dione 
• 144835-53-0 (3aR,6aS)-5-(3,5-Dichloro-phenyl)-6a-methyl-3-(4-nitro-phenyl)-3a,6a-dihydro-pyrrolo[3,4-d]isoxazole-4,6-dione 
• 144835-50-7 (3aR,6aS)-5-(3,5-Dichloro-phenyl)-6a-methyl-3-p-tolyl-3a,6a-dihydro-pyrrolo[3,4-d]isoxazole-4,6-dione 
• 144835-58-5 (3aR,6aS)-3-(2,6-Dichloro-phenyl)-5-(3,5-dichloro-phenyl)-6a-methyl-3a,6a-dihydro-pyrrolo[3,4-d]isoxazole-4,6-dione 
• 144835-62-1 3-(2-fluorophenyl)-5-(3,5-dichlorophenylcarbamoyl)-5-hydroxymethyl-5-methylisoxazoline 
• 144835-65-4 3-(2-fluorophenyl)-5-(3,5-dichlorophenyl)-4-cis-hydroxy-6a-methyl-6-oxo-3a,4,6,6a-tetrahydropyrrolo<3,4-d>isoxazole 

Relevant academic research and scientific papers

Anti-leishmanial and cytotoxic activities of a series of maleimides: Synthesis, biological evaluation and structure-activity relationship

In the present study, 45 maleimides have been synthesized and evaluated for anti-leishmanial activities against L. donovani in vitro and cytotoxicity toward THP1 cells. All compounds exhibited obvious anti-leishmanial activities. Among the tested compounds, there were 10 maleimides with superior anti-leishmanial activities to standard drug amphotericin B, and 32 maleimides with superior anti-leishmanial activities to standard drug pentamidine, especially compounds 16 (IC50 50 50 > 10 μg/mL). The anti-leishmanial activities of 16 and 42 were 10 times better than that of amphotericin B. The structure and activity relationship (SAR) studies revealed that 3,4-non-substituted maleimides displayed the strongest anti-leishmanial activities compared to those for 3-methyl-maleimides and 3,4-dichloro-maleimides. 3,4-dichloro-maleimides were the least cytotoxic compared to 3-methyl-maleimides and 3,4-non-substituted maleimides. The results show that several of the reported compounds are promising leads for potential anti-leishmanial drug development.

SMALL MOLECULE LFA-1 INHIBITORS

The present invention relates to novel compounds which are capable of inhibiting the interaction of LFA-1 with its counter ligands.